Pharmaceutical compositions containing anticholinergics and EGFR kinase inhibitors

• US 20050165013A1
• Filed: 03/23/2005
• Published: 07/28/2005
• Est. Priority Date: 07/09/2002
• Status: Abandoned Application

• Current Assignee: Boehringer Ingelheim Pharma GmbH & Company Kg (C.H. Boehringer Sohn AG & Co. KG)
• Original Assignee: Boehringer Ingelheim Pharma GmbH & Company Kg (C.H. Boehringer Sohn AG & Co. KG)
• Inventors: Meade, Christopher J. M., Pairet, Michel, Pieper, Michael P.
• Application Number:
  US11/087,153
• Publication Number:
  US 20050165013A1
• Time in Patent Office: Days
• US Class Current: 514/234.200
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/46 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
• CPC Class Codes: A61K 31/47 Quinolines; Isoquinolines
• CPC Class Codes: A61K 31/4745 condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48
• CPC Class Codes: A61K 31/505 Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0073 Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M

Abstract

The present invention relates to novel pharmaceutical compositions based on new anticholinergics and EGFR kinase inhibitors, processes for preparing them and their use in the treatment of respiratory diseases.

Claims

1. A pharmaceutical composition comprising:

(a) an anticholinergic of formula 1

wherein X⁻

is an anion with a single negative charge; and

(b) an EGFR kinase inhibitor, wherein the EGFR kinase inhibitor is optionally in the form of an enantiomer, a mixture of enantiomers, a racemate, a solvate, or a hydrate thereof,

optionally together with one or more pharmaceutically acceptable excipients.

2. The pharmaceutical composition according to claim 1, wherein X⁻

is an anion selected from chloride, bromide, iodide, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate, and p-toluenesulfonate.

3. The pharmaceutical composition according to claim 1, wherein X⁻

is a negatively charged anion selected from chloride, bromide, 4-toluenesulfonate, and methanesulfonate.

4. The pharmaceutical composition according to claim 1, wherein X⁻

is bromide.

5. The pharmaceutical composition according to claim 1, wherein the EGFR kinase inhibitor is selected from:

4-[(3-chloro-4-fluorophenyl)amino]-7-(2-{4-[(S)-(2-oxotetrahydrofuran-5-yl)-carbonyl]piperazin-1-yl}ethoxy)-6-[(vinylcarbonyl)amino]quinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-7-[2-((S)-6-methyl-2-oxomorpholin-4-yl)ethoxy]-6-[(vinylcarbonyl)amino]quinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-7-[4-((R)-6-methyl-2-oxomorpholin-4-yl)butyloxy]-6-[(vinylcarbonyl)amino]quinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-7-[4-((S)-6-methyl-2-oxomorpholin-4-yl)butyloxy]-6-[(vinylcarbonyl)amino]quinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-diethylamino)-1-oxo-2-buten-1-yl]-amino}-7-cyclopropylmethoxyquinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-{N-[2-(ethoxycarbonyl)ethyl]-N-[(ethoxycarbonyl)methyl]amino}-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmethoxyquinazoline;

4-[(R)-(1-phenylethyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline;

4-[(R)-(1-phenylethyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxyquinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-((R)-6-methyl-2-oxomorpholin-4-yl-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-((R)-6-methyl-2-oxomorpholin-4-yl)-1-oxo-2-buten-1-yl]amino-}-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-((R)-2-methoxymethyl-6-oxomorpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-[2-((S)-6-methyl-2-oxomorpholin-4-yl)ethoxy]-7-methoxyquinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-(2-methoxyethyl)-N-methylamino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxyquinazoline;

4-[(R)-(1-phenylethyl)amino]-6-{[4-(N,N-bis-(2-methoxyethyl)amino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline;

4-[(R)-(1-phenylethyl)amino]-6-({4-[N-(2-methoxyethyl)-N-ethylamino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline;

4-[(R)-(1-phenylethyl)amino]-6-({4-[N-(2-methoxyethyl)-N-methylamino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline;

4-[(R)-(1-phenylethyl)amino]-6-({4-[N-(tetrahydropyran-4-yl)-N-methylamino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((R)-tetrahydrofuran-3-yloxy)quinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)quinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-(2-methoxyethyl)-N-methylamino]-1-oxo-2-buten-1-yl}amino)-7-cyclopentyloxyquinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N-cyclopropyl-N-methylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxyquinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-[(R)-(tetrahydrofuran-2-yl)methoxy]quinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-[(S)-(tetrahydrofuran-2-yl)methoxy]quinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-[3-(morpholin-4-yl)propyloxy]-7-methoxyquinazoline;

4-[(3-ethynylphenyl)amino]-6,7-bis-(2-methoxyethoxy)quinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propyloxy]-6-[(vinylcarbonyl)amino]quinazoline;

4-[(R)-(1-phenylethyl)amino]-6-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine;

3-cyano-4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-ethoxyquinoline;

4-{[3-chloro-4-(3-fluorobenzyloxy)phenyl]amino}-6-(5-{[(2-methansulfonylethyl)amino]methyl}furan-2-yl)quinazoline;

Cetuximab;

Trastuzumab;

ABX-EGF; and

Mab ICR-62,

optionally in the form of a physiologically acceptable acid addition salt thereof.

6. The pharmaceutical composition according to claim 1, wherein the EGFR kinase inhibitor is selected from:

4-[(3-chloro-4-fluorophenyl)amino]-7-(2-{4-[(S)-(2-oxotetrahydrofuran-5-yl)-carbonyl]piperazin-1-yl}ethoxy)-6-[(vinylcarbonyl)amino]quinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-7-[2-((S)-6-methyl-2-oxomorpholin-4-yl)ethoxy]-6-[(vinylcarbonyl)amino]quinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-7-[4-((R)-6-methyl-2-oxomorpholin-4-yl)butyloxy]-6-[(vinylcarbonyl)amino]quinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-7-[4-((S)-6-methyl-2-oxomorpholin-4-yl)butyloxy]-6-[(vinylcarbonyl)amino]quinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-7-[4-(2,2-dimethyl-6-oxomorpholin-4-yl)butyloxy]-6-[(vinylcarbonyl)amino]quinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-diethylamino)-1-oxo-2-buten-1-yl]-amino}-7-cyclopropylmethoxyquinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-{N-[2-(ethoxycarbonyl)ethyl]-N-[(ethoxycarbonyl)methyl]amino}-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmethoxyquinazoline;

4-[(R)-(1-phenylethyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline;

4-[(R)-(1-phenylethyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxyquinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-((R)-6-methyl-2-oxomorpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[bis-(2-methoxyethyl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-((R)-6-methyl-2-oxomorpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-((R)-2-methoxymethyl-6-oxomorpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-[2-((S)-6-methyl-2-oxomorpholin-4-yl)ethoxy]-7-methoxyquinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-(2-methoxyethyl)-N-methylamino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxyquinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-((S)-2-methoxymethyl-6-oxomorpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline;

4-[(R)-(1-phenylethyl)amino]-6-{[4-(N,N-bis-(2-methoxyethyl)amino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline;

4-[(R)-(1-phenylethyl)amino]-6-({4-[N-(2-methoxyethyl)-N-ethylamino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline;

4-[(R)-(1-phenylethyl)amino]-6-({4-[N-(2-methoxyethyl)-N-methylamino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline;

4-[(R)-(1-phenylethyl)amino]-6-({4-[N-(tetrahydropyran-4-yl)-N-methylamino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((R)-tetrahydrofuran-3-yloxy)quinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)quinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-(2-methoxyethyl)-N-methylamino]-1-oxo-2-buten-1-yl}amino)-7-cyclopentyloxyquinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N-cyclopropyl-N-methylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxyquinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-[(R)-(tetrahydrofuran-2-yl)methoxy]quinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-[(S)-(tetrahydrofuran-2-yl)methoxy]quinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-dimethylaminocyclohexyl)amino]pyrimido[5,4-d]pyrimidine; and

4-[(3-chloro-4-fluorophenyl)amino]-6-[3-(morpholin-4-yl)propyloxy]-7-methoxyquinazoline, optionally in the form of a physiologically acceptable acid addition salt thereof.

7. The pharmaceutical composition according to claim 1, wherein the EGFR kinase inhibitor is selected from:

4-[(3-chloro-4-fluorophenyl)amino]-7-[4-((R)-6-methyl-2-oxomorpholin-4-yl)butyloxy]-6-[(vinylcarbonyl)amino]quinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-7-[4-((S)-6-methyl-2-oxomorpholin-4-yl)butyloxy]-6-[(vinylcarbonyl)amino]quinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-7-(2-{4-[(S)-(2-oxotetrahydrofuran-5-yl)-carbonyl]piperazin-1-yl}ethoxy)-6-[(vinylcarbonyl)amino]quinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-7-[2-((S)-6-methyl-2-oxomorpholin-4-yl)ethoxy]-6-[(vinylcarbonyl)amino]quinazoline;

4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-{N-[2-(ethoxycarbonyl)ethyl]-N-[(ethoxycarbonyl)methyl]amino}-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmethoxyquinazoline;

4-[(R)-(1-phenylethyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline; and

4-[(3-chloro-4-fluorophenyl)amino]-6-[3-(morpholin-4-yl)propyloxy]-7-methoxyquinazoline,

optionally in the form of a physiologically acceptable acid addition salt thereof.

8. The pharmaceutical composition according to claim 1, wherein the weight ratios of the anticholinergic to the EGFR kinase inhibitor are in the range from 1:

300 to 60;

1.

9. The pharmaceutical composition according to claim 1, wherein the weight ratios of the anticholinergic to the EGFR kinase inhibitor are in the range from 1:

200 to 30;

1.

10. The pharmaceutical composition according to claim 1, wherein a single dose for administration corresponds to a dose of the active substance combination of the anticholinergic and the EGFR kinase inhibitor of 1000 μ

g to 100,000 μ

g.

11. The pharmaceutical composition according to claim 1, wherein a single dose for administration corresponds to a dose of the active substance combination of the anticholinergic and the EGFR kinase inhibitor of 1500 μ

g to 50,000 μ

g.

12. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is in the form of a formulation suitable for inhalation.

13. The pharmaceutical composition according to claim 12, wherein the pharmaceutical composition is an inhalable powder, propellant-containing inhalable aerosol, or propellant-free inhalable solution or suspension.

14. The pharmaceutical composition according to claim 13, wherein the pharmaceutical composition is an inhalable powder comprising the anticholinergic and the EGFR kinase inhibitor in admixture with a suitable physiologically acceptable excipient selected from monosaccharides, disaccharides, oligo- and polysaccharides, polyalcohols, salts, or mixtures of these excipients with one another.

15. The inhalable powder according to claim 14, wherein the excipient has a maximum average particle size of up to 250 μ

m

16. The inhalable powder according to claim 15, wherein the excipient has a maximum average particle size of between 10 μ

m and 150 μ

m.

17. A capsule containing an inhalable powder according to claim 14.

18. The pharmaceutical composition according to claim 13, wherein the pharmaceutical composition is an inhalable powder consisting of the anticholinergic and the EGFR kinase inhibitor.

19. The pharmaceutical composition according to claim 13, wherein the pharmaceutical composition is a propellant-containing inhalable aerosol containing the anticholinergic and the EGFR kinase inhibitor in dissolved or dispersed form.

20. The propellant-containing inhalable aerosol according to claim 19, further comprising a propellant gas selected from a hydrocarbon or halohydrocarbon.

21. The propellant-containing inhalable aerosol according to claim 19, further comprising a propellant gas selected from n-propane, n-butane, isobutene, or chlorinated and/or fluorinated derivatives of methane, ethane, propane, butane, cyclopropane, or cyclobutane.

22. The propellant-containing inhalable aerosol according to claim 20, wherein the propellant gas is TG11, TG12, TG134a, TG227, or a mixture thereof.

23. The propellant-containing inhalable aerosol according to claim 20, wherein the propellant gas is TG134a, TG227, or a mixture thereof.

24. The propellant-containing inhalable aerosol according to claim 19, further comprising one or more other ingredients selected from cosolvents, stabilizers, surfactants, antioxidants, lubricants, and means for adjusting the pH.

25. The propellant-containing inhalable aerosol according to claim 19, wherein the propellant-containing inhalable aerosol contains up to 5 wt.-% of the anticholinergic and/or the EGFR kinase inhibitor active substances.

26. The pharmaceutical composition according to claim 13, wherein the pharmaceutical composition is a propellant-free inhalable solution or suspension which contains a solvent selected from water, ethanol, or a mixture of water and ethanol.

27. The inhalable solution or suspension according to claim 26, wherein the pH is 2 to 7.

28. The inhalable solution or suspension according to claim 26, wherein the pH is 2 to 5.

29. The inhalable solution or suspension according to claim 27, wherein the pH is adjusted by means of an acid selected from hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, ascorbic acid, citric acid, malic acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid, and propionic acid, or mixtures thereof.

30. The inhalable solution or suspension according to claim 26, wherein the inhalable solution or suspension optionally contains other cosolvents and/or excipients.

31. The inhalable solution or suspension according to claim 30, further comprising a cosolvent selected from ingredients which contain hydroxyl groups or other polar groups.

32. The inhalable solution or suspension according to claim 30, further comprising a cosolvent selected from isopropyl alcohol, propyleneglycol, polyethyleneglycol, polypropylene glycol, glycol ether, glycerol, polyoxyethylene alcohols, and polyoxyethylene fatty acid esters.

33. The inhalable solution or suspension according to claim 30, further comprising an excipient selected from surfactants, stabilizers, complexing agents, antioxidants and/or preservatives, flavorings, pharmacologically acceptable salts, and/or vitamins.

34. The inhalable solution or suspension according to claim 33, further comprising a complexing agent selected from edetic acid or a salt of edetic acid.

35. The inhalable solution or suspension according to claim 33, further comprising containing sodium edentate.

36. The inhalable solution or suspension according to claim 33, further comprising an antioxidant selected from ascorbic acid, vitamin A, vitamin E, and tocopherols.

37. The inhalable solution or suspension according to claim 33, further comprising a preservative selected from cetyl pyridinium chloride, benzalkonium chloride, benzoic acid, and benzoates.

38. The inhalable solution or suspension according to claim 30, consisting of the anticholinergic, the EGFR kinase inhibitor, the solvent, benzalkonium chloride, and sodium edetate.

39. The inhalable solution or suspension according to claim 30, consisting of the anticholinergic, the EGFR kinase inhibitor, the solvent, and benzalkonium chloride.

40. The inhalable solution or suspension according to claim 26, wherein the inhalable solution or suspension is a concentrate or a sterile ready-to-use inhalable solution or suspension.

41. An inhaler containing a capsule according to claim 16.

42. An inhaler containing an inhalable solution according to claim 26.

43. A nebulizer containing an inhalable solution according to claim 40.

44. A method of treating an inflammatory or obstructive disease of the respiratory tract comprising administering to a patient in need of such treatment a therapeutically effective amount of the pharmaceutical composition according to claim 1.